The synergistic effects of Apatinib combined with cytotoxic chemotherapeutic agents on gastric cancer cells and in a fluorescence imaging gastric cancer xenograft model

References

• MalvezziMBertuccioPRossoTEuropean cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?Ann Oncol20152677978625623049
   PubMed Web of Science ®Google Scholar
• RebeccaLSKimberlyDMAhmedinJCancer Statistics, 2015CA Cancer J Clin2015652529
   Web of Science ®Google Scholar
• ChenWQZhengRSPeterDCancer Statistics in China 2015CA Cancer J Clin20166611513226808342
   PubMed Web of Science ®Google Scholar
• Salah-EddinAJoergTHStephanPPhase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologieJ Clin Oncol20082691435144118349393
   PubMed Web of Science ®Google Scholar
• KangYKKangWKShinDBCapecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomized Phase III noninferiority trialAnn Oncol200920466667319153121
   PubMed Web of Science ®Google Scholar
• VanCEMoiseyenkoVMTjulandinSPhase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study GroupJ Clin Oncol200624314991499717075117
   PubMed Web of Science ®Google Scholar
• WagnerADUnverzagtSGrotheWChemotherapy for advanced gastric cancerCochrane Database Syst Rev20103CD004064
   PubMed Web of Science ®Google Scholar
• CervantesARodaDTarazonaNRosellóSPérez-FidalgoJACurrent questions for the treatment of advanced gastric cancerCancer Treat Rev201339606723102520
   PubMed Web of Science ®Google Scholar
• LordickFUnmet needs and challenges in gastric cancer: the way forwardCancer Treat Rev201440669270024656602
   PubMed Web of Science ®Google Scholar
• PowerDGKelsenDPShahMAAdvanced gastric cancer slow but steady progressCancer Treat Rev201036538439220176443
   PubMed Web of Science ®Google Scholar
• LiJQinSXuJMRandomized, double-blind, placebo-controlled Phase III Trial of Apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctionJ Clin Oncol201634131448145426884585
   PubMed Web of Science ®Google Scholar
• PeiKJiXLiHJAdvanced gastric cancer treated by apatinib: one case reportJ Chinese Oncol2016224336338
   Google Scholar
• DuJLiuBRClinical observation of Apatinib in the treatment of chemotherapy resistant advanced gastric cancerMod Oncol2016241321002104
   Google Scholar
• ZhouYYQinSKWangRFour cases of the Apatinib in the treatment of advanced gastric cancer with intractable malignant ascitesChin Clin Oncol2016215476478
   Google Scholar
• WangPYShangNNLiuZThe clinical research of Apatinib combined with Tegafur in the second line treatment of the advanced gastric cancerJ Taishan Med Col2016378919920
   Google Scholar
• ZhuXRZhuMLWangQA case report of targeted therapy with apatinib in a patient with advanced gastric cancer and high serum level of alpha-fetoproteinMedicine20169537e4610
   Web of Science ®Google Scholar
• SitohyBNagyJADvorakHFAnti-VEGF/VEGFR therapy for cancer: reassessing the targetCancer Res20127281909191422508695
   PubMed Web of Science ®Google Scholar
• MartinRRolfKAndersMDocetaxel plus Nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialLancet Oncol20141514315524411639
   PubMed Web of Science ®Google Scholar
• WangDGWangZPTianBQLiXLiSTianYTwo-hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugsInt J Urol20081543544118452462
   PubMed Web of Science ®Google Scholar
• WeidnerNCurrent pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumorsBreast Cancer Res Treat19953621691808534865
   PubMed Web of Science ®Google Scholar
• LiJZhaoXMChenLSafety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignanciesBMC Cancer20101052953620923544
   PubMed Web of Science ®Google Scholar
• AjaniJAD’AmicoTAAlmhannaKGastric cancer, version 3. 2016, NCCN clinical practice guide lines in oncologyJ Natl Compr Canc Netw201614101286131227697982
   PubMed Web of Science ®Google Scholar
• YungJBEricVCAndreaFTrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open label, randomised controlled trialLancet201037668769720728210
   PubMed Web of Science ®Google Scholar
• HansjochenWKeiMEricVCRamucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAIN BOW): a double blind, randomised phase 3 trialLancet Oncol201415111224123525240821
   PubMed Web of Science ®Google Scholar
• LinYZhaiETLiaoBAutocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancerOncotarget201787119901200228061477
   PubMedGoogle Scholar
• ZhongCYApatinib, a New Small Molecular VEGFR2 Inhibitor, Suppresses the Activity of Lung Cancer Stem Cells [EB/OL] Available from: http://wclc.ioncol.com/newsview-2233-771-0.htmlAccessed December 9, 2016
   Google Scholar
• NorrbyKMetronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth?APMIS2014122756557924164171
   PubMed Web of Science ®Google Scholar
• ChouTCTheoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studiesPharmacol Rev200658362168116968952
   PubMed Web of Science ®Google Scholar